SI2056863T1 - Zdravljenje očesnih bolezni - Google Patents

Zdravljenje očesnih bolezni

Info

Publication number
SI2056863T1
SI2056863T1 SI200731943T SI200731943T SI2056863T1 SI 2056863 T1 SI2056863 T1 SI 2056863T1 SI 200731943 T SI200731943 T SI 200731943T SI 200731943 T SI200731943 T SI 200731943T SI 2056863 T1 SI2056863 T1 SI 2056863T1
Authority
SI
Slovenia
Prior art keywords
treatment
ocular diseases
ocular
diseases
Prior art date
Application number
SI200731943T
Other languages
English (en)
Inventor
Ahmed Aftab
Lucia Desser
Bernhard Lotz
Thomas Mohr
Original Assignee
Marlyn Nutraceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marlyn Nutraceuticals, Inc. filed Critical Marlyn Nutraceuticals, Inc.
Publication of SI2056863T1 publication Critical patent/SI2056863T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI200731943T 2006-08-16 2007-08-16 Zdravljenje očesnih bolezni SI2056863T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT0137606A AT504159A1 (de) 2006-08-16 2006-08-16 Verwendung von proteasen
EP07784622.8A EP2056863B1 (en) 2006-08-16 2007-08-16 Treatment of ocular diseases
PCT/AT2007/000393 WO2008019417A2 (en) 2006-08-16 2007-08-16 Treatment of ocular diseases

Publications (1)

Publication Number Publication Date
SI2056863T1 true SI2056863T1 (sl) 2017-10-30

Family

ID=38677891

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200731943T SI2056863T1 (sl) 2006-08-16 2007-08-16 Zdravljenje očesnih bolezni

Country Status (15)

Country Link
US (1) US9795656B2 (sl)
EP (1) EP2056863B1 (sl)
JP (1) JP2010500382A (sl)
CN (1) CN101505790A (sl)
AT (1) AT504159A1 (sl)
CA (1) CA2658564A1 (sl)
DK (1) DK2056863T3 (sl)
ES (1) ES2628813T3 (sl)
HU (1) HUE034862T2 (sl)
MX (1) MX2009001745A (sl)
PL (1) PL2056863T3 (sl)
PT (1) PT2056863T (sl)
RU (1) RU2472523C2 (sl)
SI (1) SI2056863T1 (sl)
WO (1) WO2008019417A2 (sl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010029453A1 (en) * 2008-09-10 2010-03-18 Pt.Dexa Medica Composition of thrombolytic agent and anti thrombosis and also its production method
US9931381B2 (en) * 2009-11-23 2018-04-03 Prothera, Inc. Methods of comprising serratia peptidase for inhibition and treatment of biofilms related to certain conditions
FR2966734B1 (fr) * 2010-10-29 2014-07-18 Max Rombi Composition comprenant au moins une enzyme proteolytique pour son utilisation pour empecher la synthese des triglycerides
US20140154235A1 (en) 2011-05-12 2014-06-05 Smith & Nephew Orthopaedics Ag Wound debridement compositions containing seaprose and methods of wound treatment using same
RU2014145270A (ru) 2012-05-11 2016-07-10 Смит & Невью, Инк. Способ и композиция для разрушения бактериальной биопленки
ITMI20121997A1 (it) * 2012-11-23 2014-05-24 Velleja Res Srl Composizioni fibrinolitiche per la prevenzione e il trattamento degli stati flebotrombotici
ITMI20130117A1 (it) * 2013-01-25 2014-07-26 Gnosis Spa Composizioni comprendenti condroitin solfato, enzimi proteolitici e composti sulfidrilati capaci di migliorare la biodisponibilita' del condroitin solfato
US20140212405A1 (en) * 2013-01-28 2014-07-31 2294719 Ontario Limited Fibrinolytic/Proteolytic Treatment of Myofacial and Neuropathic Pain and Related Conditions
US11065310B2 (en) 2016-05-27 2021-07-20 Nattocat, LLC Compositions and methods for thromboembolism dissolution
CN109475609A (zh) 2016-07-27 2019-03-15 史密夫和内修有限公司 使用嗜热菌蛋白酶减少或消除来自表面的细菌生物膜
US11413300B2 (en) 2017-01-30 2022-08-16 Smith & Nephew, Inc. Synergistic combination of thermolysin and an antibacterial agent to reduce or eliminate bacterial biofilms from surfaces
JP7429503B2 (ja) 2019-06-24 2024-02-08 小林製薬株式会社 ナットウキナーゼを含む経口組成物
TW202202168A (zh) * 2020-07-07 2022-01-16 洪啟庭 用於改善玻璃體混濁的組成物及其應用
CN113769073A (zh) * 2021-10-15 2021-12-10 杭州鑫伟低碳技术研发有限公司 一种利用生物酶治疗眼底出血的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030612A (en) * 1994-11-22 2000-02-29 Phairson Medical Inc. Antimicrobial uses of multifunctional enzyme
TR199901703T2 (xx) * 1996-11-19 2000-07-21 G.D. Searle & Co. Siklooksijenaz-2 inhibit�rlerini anti-anjiyojenik ajanlar olarak kullanma y�ntemi.
DE19726251C2 (de) 1997-06-20 2000-03-02 Mucos Pharma Gmbh & Co Verwendung proteolytischer Enzyme zur Behandlung von Uveitis
JP2002516261A (ja) * 1998-05-22 2002-06-04 エンターメッド インコーポレイテッド セリンプロテアーゼを利用して内皮細胞増殖を阻害し血管新生を調節するための組成物と方法
WO2000001410A1 (en) * 1998-07-06 2000-01-13 Beth Israel Deaconess Medical Center Methods of inhibiting proliferative diseases by inhibiting tgf-beta mediated angiogenesis
US20040086537A1 (en) * 1998-08-20 2004-05-06 Jun Inoue Prophylactic or threapeutic composition for ocular circulation disorders
US20030027998A1 (en) * 1998-10-30 2003-02-06 Holtzman Douglas A. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
US7559718B2 (en) * 1999-01-27 2009-07-14 Trimble Navigation Limited Transducer arrangement
EP1377312A4 (en) * 2001-03-22 2004-10-06 Andel Inst Van ANTHRAX LETAL FACTOR INHIBITS TUMOR GROWTH AND ANGIOGENESIS
US20020192206A1 (en) 2001-05-05 2002-12-19 Kozarov Emil V. Methods and compositions for angioproliferative disorder treatment
US7381404B2 (en) * 2002-07-02 2008-06-03 The Regents Of The University Of California Treatment for dry macular degeneration
US20050002897A1 (en) * 2003-06-18 2005-01-06 Ulrich Haupts Biological entities and the pharmaceutical or diagnostic use thereof
US7354569B2 (en) * 2003-07-11 2008-04-08 Colgate-Palmolive Company Chewable antiplaque confectionery dental composition
WO2005056784A1 (ja) * 2003-12-15 2005-06-23 Japan Science And Technology Agency インスリン誘導性ポリペプチド
EP1735439B1 (en) * 2004-04-12 2011-11-23 Catalyst Biosciences, Inc. Cleavage of vegf and vegf receptor by wildtype and mutant mt-sp1
EP1735438A2 (en) * 2004-04-12 2006-12-27 Catalyst Biosciences Cleavage of vegf and vegf receptor by wild-type and mutant proteases
US20060083727A1 (en) * 2004-07-15 2006-04-20 Nanobac Pharmaceuticals, Inc. Methods and compositions for the treatment of diseases characterized by calcification and/or plaque formation
JPWO2006025276A1 (ja) 2004-08-31 2008-05-08 国立大学法人 熊本大学 ナットウキナーゼを含む眼科疾患の治療・予防剤
MX2008014136A (es) * 2006-05-04 2009-03-31 Fovea Pharmaceuticals Sa Combinacion que comprende un inhibidor de factor de crecimiento endotelial vascular y serina proteasa para tratar enfermedades neovasculares.

Also Published As

Publication number Publication date
CA2658564A1 (en) 2008-02-21
CN101505790A (zh) 2009-08-12
RU2472523C2 (ru) 2013-01-20
ES2628813T3 (es) 2017-08-04
WO2008019417A2 (en) 2008-02-21
EP2056863B1 (en) 2017-03-22
JP2010500382A (ja) 2010-01-07
DK2056863T3 (en) 2017-07-10
US9795656B2 (en) 2017-10-24
PT2056863T (pt) 2017-07-04
HUE034862T2 (en) 2018-03-28
EP2056863A2 (en) 2009-05-13
PL2056863T3 (pl) 2017-11-30
US20110311509A1 (en) 2011-12-22
RU2009109358A (ru) 2010-09-27
AT504159A1 (de) 2008-03-15
WO2008019417A3 (en) 2008-05-29
MX2009001745A (es) 2009-07-10

Similar Documents

Publication Publication Date Title
PT2056863T (pt) Tratamento de doenças oculares
EP2187743A4 (en) FORMULATIONS FOR THE TREATMENT OF DISEASES OR EYE DISORDERS
HK1201046A1 (en) Methods of treating ophthalmic diseases
PL2044111T3 (pl) Celowanie czynnika H dopełniacza do leczenia chorób
HK1131047A1 (en) Treatment of inflammatory diseases
IL186749A0 (en) Dihydrothienopyrimidines for the treatment of inflammatory diseases
EP2004204A4 (en) TREATMENT OF NEURODEGENERATIVE DISEASES
EP2053982A4 (en) TREATMENT OF GLAUCOMA BY ULTRASOUND
IL190779A0 (en) Compositions for treatment of eye diseases
ZA200903862B (en) Nutritional supplement composition for treatment of ocular diseases
EP1962869A4 (en) TREATMENT OF RESPIRATORY DISEASES
EP2026822A4 (en) TOPICAL TREATMENT FOR EYE SURGERY DISEASES
ZA200806808B (en) Treatment of stressed patients
PL2148667T3 (pl) Stosowanie pochodnych cycloheksanoheksolu w leczeniu chorób oczu
GB0610183D0 (en) Treatment of neurodegenerative diseases
GB0523961D0 (en) The treatment of ophthalmic diseases
GB0523964D0 (en) The treatment of ophthalmic diseases
GB0428218D0 (en) Medicament for Treatment of Inflammatory Diseases
GB0623740D0 (en) Treatment of disease
GB0622136D0 (en) Treatment of gastrointestinal diseases
EP1846013A4 (en) TREATMENT OF SKIN DISEASES
ZA200904660B (en) Treatment of IL-1-Beta related diseases
GB0622137D0 (en) Treatment of gastrointestinal diseases
GB0700755D0 (en) The Treatment of ophthalmic diseases
GB0801511D0 (en) The treatment of ophthalmic diseases